Laurus Labs' Q4 FY 2025-26 Quarterly Results

Result Summary

• Laurus Labs Ltd reported a 2.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 2.5%.
• Its expenses for the quarter were up by 0.3% QoQ and down 0.3% YoY.
• The net profit increased 12.0% QoQ and increased 21.2% YoY.
• The earnings per share (EPS) of Laurus Labs Ltd stood at 5.17 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Laurus Labs Ltd is a well-known pharmaceutical company primarily engaged in the research and development, manufacturing, and sales of generic and active pharmaceutical ingredients (APIs). The company operates in the healthcare and pharmaceuticals industry, providing a range of products including antiretrovirals, Hepatitis C, oncology, and other therapeutic categories. As of the data available up to October 2023, there are no specific recent major developments mentioned for Laurus Labs Ltd. The company is recognized for its focus on innovation and maintaining a robust product portfolio to cater to various markets worldwide.

Revenue

For the fourth quarter of the fiscal year 2026 (Q4FY26), Laurus Labs Ltd reported a total income of ₹1823.37 crores. This reflects a quarter-over-quarter (QoQ) increase of 2.2% compared to ₹1784.05 crores in Q3FY26. Additionally, there is a year-over-year (YoY) increase of 2.5% from ₹1778.87 crores in Q4FY25. This growth in revenue indicates a positive trajectory in the company’s income generation capabilities over both the quarterly and annual periods. The company’s ability to sustain and grow its revenue base is indicative of its operational efficiency and market penetration.

Profitability

In Q4FY26, Laurus Labs Ltd achieved a profit before tax of ₹361.37 crores, marking a significant QoQ increase of 10.7% from ₹326.56 crores in Q3FY26. On a YoY basis, this represents a 15.7% increase from ₹312.34 crores in Q4FY25. The profit after tax for the same quarter was ₹282.09 crores, showing a 12.0% QoQ increase from Q3FY26's ₹251.88 crores, and a 21.2% YoY rise from ₹232.77 crores in Q4FY25. Earnings per share (EPS) also increased to ₹5.17 from ₹4.65 in the previous quarter, and from ₹4.33 a year earlier, representing QoQ and YoY increases of 11.2% and 19.4%, respectively. These profitability metrics underscore the company's strong financial performance in the specified timeframe.

Operating Metrics

During the fourth quarter of FY26, Laurus Labs Ltd reported total expenses of ₹1462.00 crores, which is a slight QoQ increase of 0.3% from ₹1457.49 crores in Q3FY26 and a slight decrease of 0.3% YoY from ₹1466.53 crores in Q4FY25. The tax expense for the quarter was ₹79.46 crores, up 8.2% QoQ from ₹73.45 crores and a 1.3% increase YoY from ₹78.47 crores. These operating metrics reflect the company's ability to manage its cost structure effectively while accommodating revenue growth. The financial data suggests a stable expense management strategy while the company continues to grow its revenue and improve profitability.